Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Ras Gene02:38

The Ras Gene

6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Discovery of NKT2152, a Potent and Selective HIF-2α Inhibitor with Favorable Pharmacokinetic Properties.

ACS medicinal chemistry letters·2026
Same author

The effect of personality on likelihood of contracting SARS-CoV-2 in the United States.

Personality and individual differences·2026
Same author

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same author

Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Comparing civil legal actions among international and Canadian or American medical graduates in Canada: a retrospective cohort study.

BMJ open·2026
Same author

NF1 and SPRED1/2 cooperate through RAS-MAPK-independent functions.

Proceedings of the National Academy of Sciences of the United States of America·2026

相关实验视频

Updated: Jun 14, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

通过阻断RAS- PI3Kα相互作用,BBO-10203可以抑制瘤生长而不会引起高血糖.

Dhirendra K Simanshu1, Rui Xu2, James P Stice2

  • 1NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.

Science (New York, N.Y.)
|June 12, 2025
PubMed
概括

在临床前模型中,BBO-10203是一种针对酸3-酶α (PI3Kα) 的新型口服药物,可显著抑制瘤. 这种PI3Kα抑制剂有效地减少瘤生长而不会引起高血糖症.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.8K

相关实验视频

Last Updated: Jun 14, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.8K

科学领域:

  • 癌症学
  • 分子生物学
  • 药理学

背景情况:

  • 酸3-激酶α (PI3Kα) 是一种关键的信号酶,涉及各种癌症.
  • 通过RAS激活PI3Kα在瘤发育和进展中起着至关重要的作用.
  • 在多种瘤类型中,PIK3CA,KRAS和HER2放大/过度表达的致癌突变是常见的驱动因素.

研究的目的:

  • 在临床前癌症模型中评估口服PI3Kα抑制剂BBO-10203的疗效.
  • 研究BBO-10203的作用机制,重点关注其与PI3Kα的RAS结合域的特定结合.
  • 评估BBO-10203作为单一治疗和与其他向药物的结合的潜力.

主要方法:

  • 在临床前的癌症模型中,BBO-10203是口服的.
  • 在具有特定瘤突变或放大的瘤中评估PI3Kα激活的抑制.
  • 在各种瘤类型中评估瘤生长抑制,包括具有KEAP1和STK11突变的瘤.
  • 组合疗法包括CDK4/ 6,ER,HER2和KRAS- G12C的抑制剂.

主要成果:

  • BBO-10203与PI3Kα的RAS结合域结合,防止其被RAS蛋白激活.
  • 这种药物在瘤性KRAS,PIK3CA突变或HER2放大/过度表达的瘤中表现出PI3Kα抑制.
  • 在多种瘤类型中观察到显著的瘤生长抑制.
  • 在组合疗法中,特别是在KEAP1和STK11突变的瘤中,观察到更高的疗效.

结论:

  • 在临床前模型中,BBO-10203是一种强大的PI3Kα抑制剂,具有广泛的抗瘤活性.
  • 当与其他向治疗,包括CDK4/ 6,ER,HER2和KRAS- G12C抑制剂结合使用时,该药物的疗效会增强.
  • 在不引起高血糖的情况下,BBO-10203具有抗瘤作用,这表明其具有明显的治疗窗口.